Advertisement

Thromboembolism in Adults with St. Jude Medical® Valves on Ticlopidine and Aspirin Maintenance

  • H. M. Kim
  • K. T. Kim

Abstract

We evaluated the risks of thromboembolism, valve thrombosis, anticoagulant hemorrhage, and sudden cardiac death in two groups of patients. The groups were similar in age, sex, and associated cardiovascular diseases except for the method of prevention of thromboembolism and length of follow-up. The group receiving warfarin consisted of 74 patients with 85 valves. Patients were maintained on long-term warfarin therapy. Eight of the 74 patients in the warfarin group did not survive the operative period, for a mortality of 10.8%. Prevention of thromboembolism was managed solely with warfarin to maintain the prothrombin time of 1.5 times control. The group receiving ticlopidine and aspirin consisted of 88 patients with 93 heart valves. Patients received ticlopidine (500 mg) and aspirin (500 mg) daily for 3 months postoperatively and in half doses thereafter. Three of the 88 patients did not survive the operative period, for an operative mortality of 3.4%. Warfarin was added postoperatively for 3 months for 39 of the 88 ticlopidine and aspirin group patients with high risk factors. Patients were follow ed-up from 36 to 120 months, with a mean of 33.5 months, in the warfarin group; and 1 to 36 months, with a mean of 8.5 months in the ticlopidine and aspirin group. At the most recent follow-up, 90% of the patients were in New York Heart Association (NYHA) Classes I and II. There were 5 late deaths in the warfarin group, 3 due to thromboembolism and 2 due to anticoagulant-related cerebral hemorrhage. Nonfatal attacks of thromboembolism and anticoagulant-related hemorrhage were noted in 10 other cases during follow-up. There were no late deaths in the ticlopidine and aspirin group during the short period of follow-up, except i case 35 days after mitral valve replacement, already included in the operative deaths. There was no case of primary valve failure or anticoagulant-related hemorrhage, except minor epistaxis and hypermenorrhea in the ticlopidine and aspirin group during this follow-up. It is our strong impression that combining ticlopidine and aspirin in low-risk adults has a synergistic effect and had superior results in preventing thromboembolism without anticoagulant-related hemorrhage. Warfarin is also necessary in high-risk adults for preventing early thrombus formation along the valve suture line. We recommend antiplatelet aggregator therapy with ticlopidine and aspirin in low-risk adult patients with ST. JUDE MEDICAL® valves and additional warfarin for 3 months in the high-risk adults with ST. JUDE MEDICAL valves.

Keywords

Valve Replacement Aortic Valve Replacement Mitral Valve Replacement Aspirin Group Atrial Thrombus 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Tepley JF, Grunkemeier GL, Sutherland HD, et al. The ultimate prognosis after valve replacement: An assessment of twenty years. Ann Thorac Surg 1981; 32:111–119.CrossRefGoogle Scholar
  2. 2.
    Edmunds LH Jr. Thromboembolic complications of current cardiac valve prostheses. Ann Thorac Surg 1982; 34:96.PubMedCrossRefGoogle Scholar
  3. 3.
    Cohn LH. Thromboembolism after cardiac valve replacement. In Matloff JM (ed): Cardiac Value Replacement. Martinus Nijhoff Publishing, Boston 1984; pp 9–16.Google Scholar
  4. 4.
    Björk VO, Lindblom D. The monostrut Björk-Shiley heart valve. Scand J Thorac Cardiovasc Surg 1985; 19(1):13–19.PubMedCrossRefGoogle Scholar
  5. 5.
    Kim JH. Cardiac valve replacement and anticoagulant therapy. J Korea Thorac Cardiovasc Surg 1978; 11:303–312.Google Scholar
  6. 6.
    Arom KV, Nicoloff DM, Kersten TE, et al. Six years of experience with the St. Jude Medical valvular prosthesis. Circulation 1985 Sep; 72(3pt 2):II 153–158.Google Scholar
  7. 7.
    Day HJ. Overview: Clinical experiences with ticlopidine. In Gordon JI (ed): Ticlopidine: Quo Vadis? AAS 15, Birkhauser Verlag, Basel 1984; p 287.Google Scholar
  8. 8.
    Kim KT, Kim HM. A clinical and experimental study on prevention of thromboembolism with antiplatelet drug after cardiac valve replacement. Korea Univ Med J 1987; 24:1–12.Google Scholar
  9. 9.
    Gajewski J, Singer RB. Mortality in an insured population with atrial fibrillation. JAMA 1981; 245:1540–1544.PubMedCrossRefGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1989

Authors and Affiliations

  • H. M. Kim
  • K. T. Kim

There are no affiliations available

Personalised recommendations